Most investors still file McKesson under "drug wholesaler": enormous revenue, razor-thin spreads, little to get excited about. The latest quarter suggests that label is increasingly out of date. The largest of America's three big drug distributors is steadily tilting toward higher-margin work, and the profit mix, not the headline sales figure, is where the long-term story now sits.
Consider the second-quarter split. Oncology and prescription technology together made up roughly 15% of revenue yet produced nearly 37% of adjusted segment operating profit. The technology unit is the extreme case: just 1.4% of sales, but about 15% of segment profit, thanks to a margin above 20% versus roughly 1.14% in the legacy North American wholesale business. Oncology services run at nearly 2.9%, and underlying profit there grew about 23% once a prior-year one-time gain is stripped out. Same company, very different economics.
Management has been reshaping the portfolio to lean further in that direction. The Precision Medicine Group deal closed on Nov. 2, and a $1.4 billion, 49% stake in home-infusion provider Option Care Health is expected to close in the first half of 2027. The slower-growing medical-surgical arm, where profit fell 10% last quarter, is slated to be renamed Wellverse and spun off through an IPO in the second half of 2027. An agreement in principle to extend the CVS Health distribution relationship through June 2032 would also give the company's largest customer a longer runway and remove a lingering overhang.
The financial follow-through is what makes this more than a narrative. Fiscal 2027 adjusted earnings guidance was lifted to $45.60-$46.40 per share, implying 17% to 19% growth. Free cash flow is expected to land between $4.5 billion and $4.9 billion, roughly a 3.8% yield on a market value near $124 billion. About $5 billion of buybacks are planned for the year, and the dividend was raised 15% earlier in the fiscal year. Shrinking the share count at that pace quietly compounds per-share results even if the underlying business simply grows at a steady clip.
Valuation is more nuanced than the rally implies. After a gain of more than 30% this year, the shares trade near 23 times guided earnings, still under a five-year median of about 25 times. Higher interest rates argue for a lower multiple; a richer business mix argues for a higher one. The cushion has narrowed, and the premium to peer Cardinal Health leaves less room for stumbles.
The risks are real and worth respecting. Changes to the 340B drug-pricing program or Medicare Part D economics could pressure distributor margins, opioid-related liabilities have not vanished, and GLP-1 volumes, a meaningful tailwind, are starting to normalize while carrying thin margins. The CVS extension is not yet final, and splitting off a business while integrating acquisitions is rarely seamless.
So what for long-term investors? Durable compounders are often disguised as boring businesses. Three scaled players move most of the nation's drugs, and licensing, compliance and network density protect that franchise. What is changing is the quality of earnings layered on top of it. The thing to watch over the next several quarters is not the revenue line but whether specialty and technology keep growing their share of operating profit, and whether free cash flow keeps funding buybacks and dividends without stretching the balance sheet.